Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists

被引:59
作者
Berg, KA
Maayani, S
Goldfarb, J
Clarke, WP
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA
[2] Mt Sinai Med Ctr, Dept Anesthesiol, New York, NY 10029 USA
[3] Mt Sinai Med Ctr, Dept Pharmacol, New York, NY 10029 USA
来源
ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS | 1998年 / 861卷
关键词
D O I
10.1111/j.1749-6632.1998.tb10180.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is now considerable evidence that a single receptor subtype can couple to multiple effector pathways within a cell. Recently, Kenakin proposed a new concept, termed "agonist-directed trafficking of receptor stimulus", that suggests that agonists may be able to selectively activate a subset of multiple signaling pathways coupled to a single receptor subtype. 5-HT2A and 5-HT2C receptors couple to phospholipase C-(PLC) mediated inositol phosphate (IP) accumulation and PLA(2)-mediated arachidonic acid (AA) release. Relative efficacies of agonists (referenced to 5-HT) differed depending upon whether LP accumulation or AA release aas measured. For the 5-HT2C receptor system, some agonists (e.g. TFMPP) preferentially activated the PLC-IP pathway, whereas others (e.g. LSD) favored PLA(2)-AA. As expected, EC50's of agonists did not differ between pathways, For the 5-HT2A receptor system, all agonists tested had greater relative efficacy for PLA(2)-AA than for PLC-LP. In contrast, relative efficacies were not different for 5-HT2A agonists when sequential effects in a pathway were measured (IP accumulation vs. calcium mobilization). These data strongly support the agonist-directed trafficking hypothesis.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 13 条
[1]  
BERG KA, 1994, MOL PHARMACOL, V46, P477
[2]   Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus [J].
Berg, KA ;
Maayani, S ;
Goldfarb, J ;
Scaramellini, C ;
Leff, P ;
Clarke, WP .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :94-104
[3]  
Berg KA, 1996, MOL PHARMACOL, V50, P1017
[4]  
CLARK AJ, 1937, HEFFNERS HDB DEXP PH, V4
[5]   The elusive nature of intrinsic efficacy [J].
Clarke, WP ;
Bond, RA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (07) :270-276
[6]  
COSTA T, 1992, MOL PHARMACOL, V41, P549
[7]  
Furchgott R., 1966, ADV DRUG RES, V3, P21
[8]  
Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429
[9]   AGONIST-RECEPTOR EFFICACY .2. AGONIST TRAFFICKING OF RECEPTOR SIGNALS [J].
KENAKIN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (07) :232-238
[10]  
Kenakin T, 1996, PHARMACOL REV, V48, P413